Addition of History of Intussusception as a Contraindication for Rotavirus Vaccination
This article, published in Morbidity and Mortality Weekly Report, reports on the revision that the US Food and Drug Administration has approved for the prescribing information and patient labeling for rotavirus vaccines manufactured by GlaxoSmithKline Biologicals (Rotarix) and Merck & Co. (RotaTeq) to include history of intussusception as a contraindication. This change is based on new research regarding the potential increased risk for intussusception following rotavirus vaccine administration.
Author(s): US Centers for Disease Control and Prevention
Visit web page (English)
(Located at www.cdc.gov)